References
- Ventilation with lower tidal volumes as compared with traditional tidal volumes for
acute lung injury and the acute respiratory distress syndrome. The Acute
Respiratory Distress Syndrome Network. N Engl J Med, 2000. 342(18): p. 1301- - 8.Gattinoni, L., P. Caironi, and E. Carlesso, How to ventilate patients with^ acute
lung injury and acute respiratory distress syndrome. Curr Opin Crit Care, 2005.
11(1): p. 69-76. - Hickling, K.G., S.J. Henderson, and R. Jackson, Low mortality associated with
low volume pressure limited ventilation with permissive hypercapnia in adult respiratory distress syndrome. Intensive Care Med, 1990. 16(6): p. 372severe -7. - Hickling, K.G., et al., Low mortality rate in adult respiratory distress syndrome
using low-volume, pressure-limited ventilation with permissive hypercapnia: a
prospective study. Crit Care Med, 1994. 22(10): p. 1568-78. - Jardin, F., et al., Improved prognosis of acute respiratory distress syndrome 15 years on. Intensive Care Med, 1999. 25(9): p. 936-41.
- Deans, K.J., et al., The efficacy of drotrecogin alfa depends on severity of illness.
Crit Care Med, 2004. 32(11): p. 2347. - Eichacker, P.Q. and C. Natanson, Recombinant human activated protein C in
sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit
Care Med, 2003. 31(1 Suppl): p. S94-6. - Eichacker, P.Q., et al., Risk and the efficacy of antiinflammatory agents:
retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med,
2002. 166(9): p. 1197 - 205. - Minneci, P.C., et al., Metaduring sepsis depends on the dose. Ann Intern Med, 2004. 141(1): p. 47-analysis: the effect of steroids on survival and shock -56.
- Minneci, P.C., et al., Antithrombotic therapies for sepsis: a need for more studies.
Crit Care Med, 2006. 34(2): p. 538-41. - Sweeney, D.A., et al., Once is not enough: clinical trials in sepsis. Intensive Care
- Med, 2008. 34(11): p. 1955Abraham, E., et al., Drotrecogin alfa (activated) for adults with severe sepsis and -60.^
a low risk of death. N Engl J Med, 2005. 353(13): p. 1332-41. - Bernard, G.R., et al., Efficacy and safety of recombinant human activated protein
C for severe sepsis. N Engl J Med, 2001. 344(10): p. 699-709. - Goldstein, B., et al., ENHANCE: results of a glalfa (activated) in children with severe sepsis. Pediatr Crit Care Med, 2006. 7(3): obal open-label trial of drotrecogin
p. 200-11. - Haley, M., et al., Activated protein C in sepsis: emerging insights regarding its
mechanism of action and clinical effectiveness. Curr Opin Infect Dis, 2004. 17(3):
p. 205-11.